Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex

被引:19
|
作者
Garcia-Fernandez, Sergio [1 ,2 ,8 ]
Bala, Yohann [3 ]
Armstrong, Tom [4 ]
Garcia-Castillo, Maria [1 ,2 ,8 ]
Burnham, Carey-Ann D. [5 ]
Wallace, Meghan A. [5 ]
Hardy, Dwight [6 ]
Zambardi, Gilles [7 ]
Canton, Rafael [1 ,2 ,8 ]
机构
[1] Hosp Univ Ramon & Cajal, Serv Microbiol, Madrid, Spain
[2] IRYCIS, Madrid, Spain
[3] BioMerieux Global Clin Affairs, Marcy Letoile, France
[4] BioMerieux Global Clin Affairs, Hazelwood, MO USA
[5] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA
[6] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[7] BioMerieux, La Balme Les Grottes, France
[8] REIPI, Madrid, Spain
关键词
piperacillin-tazobactam; Etest; antimicrobial susceptibility testing; gradient diffusion; Enterobacterales; Pseudomonas aeruginosa; Acinetobacter baumannii complex; ESCHERICHIA-COLI; LACTAMASE;
D O I
10.1128/JCM.01042-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Piperacillin-tazobactam (P/T) is a beta-lactam-beta-lactamase inhibitor combination frequently used in the hospital setting. Etest is a gradient diffusion method that represents an alternative to broth microdilution (BMD) for performing antimicrobial susceptibility testing. We conducted a multicenter evaluation of the performance of the new P/T Etest compared to that of BMD following U.S. Food and Drug Administration (FDA) and International Standards Organization (ISO) standard ISO 20776-2 criteria using Clinical and Laboratory Standards Institute (CLSI)-FDA and European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive breakpoints, respectively. A total of 977 isolates (775 Enterobacterales isolates, 119 Pseudomonas aeruginosa isolates, and 83 Acinetobacter baumannii complex isolates) were tested. Overall essential agreement (EA) was 96.4% and 96.6% for Enterobacterales when FDA and ISO 20776-2 criteria, respectively, were followed. EA was 98.3% for P. aeruginosa and 91.6% for the A. baumannii complex when both the FDA and ISO criteria were followed. Applying CLSI-FDA breakpoints, categorical agreement (CA) reached 93.0%, 93.3%, and 89.2% for the Enterobacterales, P. aeruginosa, and the A. baumannii complex, respectively. Two very major errors (VMEs; 1.1%) were found among the Enterobacterales (for 2 Klebsiella pneumoniae isolates). No additional major errors (MEs) or VMEs were found. Applying EUCAST breakpoints, CA was 94.8% and 95.8% for Enterobacterales and P. aeruginosa, respectively (no breakpoints are currently available for the A. baumannii complex). No VMEs were observed among the Enterobacterales, but 2 (0.4%) MEs were found. Among the P. aeruginosa isolates, 2 (6.9%) VMEs and 3 (33%) MEs were observed. These errors resulted when P/T Etest MICs were 1 doubling dilution apart from the BMD MICs. In conclusion, the new P/T Etest represents an accurate tool for performing antimicrobial susceptibility testing of Enterobacterales, P. aeruginosa, and A. baumannii complex isolates with limited category errors.
引用
收藏
页数:9
相关论文
共 25 条
  • [1] Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa
    Bailey, Adam L.
    Armstrong, Tom
    Dwivedi, Hari-Prakash
    Denys, Gerald A.
    Hindler, Janet
    Campeau, Shelley
    Traczewski, Maria
    Humphries, Romney
    Burnham, Carey-Ann D.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2018, 56 (09)
  • [2] Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam
    Gagliotti, Carlo
    Sarti, Mario
    Sabia, Carla
    Gargiulo, Raffaele
    Rossolini, Gian Maria
    Carillo, Carmelina
    Cassani, Carla
    Cipolloni, Antonio Paolo
    Pedna, Federica
    Rossi, Maria Rita
    Incerti, Silvia Storchi
    Testa, Giovanna
    Venturelli, Claudia
    Moro, Maria Luisa
    NEW MICROBIOLOGICA, 2011, 34 (01): : 97 - 99
  • [3] Microcalorimetric method to determine ceftazidime and piperacillin-tazobactam susceptibility in Pseudomonas aeruginosa
    Esarte Lopez, L.
    Lago Rivero, N.
    Vazquez, C.
    Mato Corzon, M. M.
    Legido Soto, J. L.
    JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2015, 121 (01) : 353 - 360
  • [4] Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMerieux) for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa
    Jean, Sophonie
    Garrett, Sheri
    Anglade, Claire
    Bridon, Laurence
    Davies, Leanne
    Garner, Omai B.
    Richards, Jennifer
    Wallace, Meghan
    Wootton, Mandy
    Burnham, Carey-Ann D.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (01)
  • [5] Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
    Papadomanolaki, Arhodoula
    Siopi, Maria
    Karakosta, Polyxeni
    Vourli, Sophia
    Pournaras, Spyros
    ANTIBIOTICS-BASEL, 2022, 11 (07):
  • [6] Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobactetiaceae and Pseudomonas aeruginosa
    Karlowsky, JA
    Weaver, MK
    Thornsberry, C
    Dowzicky, MJ
    Jones, ME
    Sahm, DF
    JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (07) : 3339 - 3343
  • [7] Rapid disc diffusion antibiotic susceptibility testing for Pseudomonas aeruginosa, Acinetobacter baumannii and Enterococcus spp.
    Hombach, Michael
    Jetter, Marion
    Bloechliger, Nicolas
    Kolesnik-Goldmann, Natalia
    Keller, Peter M.
    Boettger, Erik C.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (02) : 385 - 391
  • [8] Evaluation of Vitek2 and BD Phoenix in antimicrobial susceptibility testing of Acinetobacter baumannii and Pseudomonas aeruginosa
    Jekarl, Dong Wook
    Han, Sang Bong
    Kim, Yoon Joo
    Shin, Sang Hyun
    Park, Kang Gyun
    Park, Jung Jun
    Han, Kyungja
    Park, Yeon-Joon
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2010, 67 (04) : 384 - 386
  • [9] Multicenter Evaluation of Ceftazidime-Avibactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa on the Vitek 2 System
    Humphries, Romney
    Campeau, Shelley
    Davis, Thomas E.
    Nagaro, Kristin J.
    LaBombardi, Vincent J.
    Franklin, Simone
    Heimbach, Lisa
    Dwivedi, Hari P.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (03)
  • [10] Multicenter Clinical Evaluation of Vitek 2 Meropenem-Vaborbactam for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
    Dwivedi, Hari P.
    Franklin, Simone
    Chandrasekaran, Sukantha
    Garner, Omai
    Traczewski, Maria M.
    Beasley, Denise
    Procop, Gary W.
    Tuohy, Marion
    Wilson, Deborah
    Bala, Yohann
    Pincus, David H.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2022, 60 (01)